Intermediate- 2 Risk Myelofibrosis in a 68-Year-Old Woman

Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.

Dr. Bose shares his perspective on the factors he considers when deciding on initial therapy for myelofibrosis, including his approach to timing of treatment initiation and how splenomegaly influences his choice of JAK inhibitors.

Dr. Bose discusses the key findings from the COMFORT I and II trials and how the overall survival data has impacted the way he manages patients with myelofibrosis, along with the factors that most inform his treatment decisions.

Dr. Bose reviews the efficacy and safety findings from various studies on JAK inhibitors, including JAKARTA, PERSIST-1, PERSIST-2, SIMPLIFY-1 & 2, and MOMENTUM, and how these data inform his treatment choices.

Dr. Bose discusses when he typically initiates ruxolitinib for his intermediate- or high-risk myelofibrosis patients.

Dr. Bose shares his perspective on how he monitors and manages anemia for patients on ruxolitinib, including when he would consider dose reduction or transfusion.

Dr. Bose discusses his perspective on quality-of-life preservation for his patients with myelofibrosis, including the symptoms that have the most negative impact on patients' quality of life.

Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.